Dual path immunoassay device

Inventors

Esfandiari, Javanbakhsh

Assignees

Chembio Diagnostic Systems Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-8507259-B2

Patent

Publication Date

2013-08-13

Expiration Date


Abstract

The systems of the invention include test cells with a first sorbent material defining a first flow path for a solution, a second sorbent material defining a second flow path distinct from the first flow path for a sample, and a test line or test site with immobilized antigens or antibodies or other ligand binding molecules such as aptamers, nucleic acids, etc. located at the junction of the first and second sorbent materials. The first and second sorbent strips touch each other at the test site location.

Core Innovation

The invention describes a dual-path immunoassay device in which the liquid sample and ligand migrate along one sorbent path, while a solution carrying a marker conjugate migrates along a distinct path. The paths meet at a shared test site, where binding agents selectively bind to one another. The sample flows laterally to the test site rather than wetting it immediately upon application.

The described problem is that aggregation can impede conventional lateral-flow assays. The separate migration paths allow the ligand to be captured before marker binding, avoiding the aggregation that can impede those assays. A specific embodiment detects HIV-1 p24 using a biotin-bound monoclonal antibody and streptavidin at the test site, followed by a colored latex-antibody conjugate from the separate path.

Claims Coverage

The relevant claims include one independent claim covering five inventive features for determining the presence of a ligand in a liquid sample.

Distinct sorbent migration paths

The device has a first sorbent strip that receives a solution and defines a first migration path, and a second sorbent strip that receives the liquid sample and defines a distinct second migration path.

Ligand-binding antibody conjugate

The second migration path includes an antibody bound to an interim binding agent. The antibody is selected to bind to the ligand when it is present in the sample.

Shared test site with selectively binding agents

A test site on or in at least one sorbent strip has an immobilized binding agent. The interim binding agent and immobilized binding agent are chosen to selectively bind well to each other, and the two strips touch at the test site.

Lateral sample flow to the test site

The second migration path extends laterally from the sample-receiving location to at least the test site, requiring time for the sample to flow there and preventing it from immediately wetting the test site upon application.

HIV-1 p24 assay configuration

Dependent claims specify HIV-1 p24 antigen, an HIV-1 p24 monoclonal antibody bound to biotin, and streptavidin as the immobilized binding agent. A further claimed configuration includes a colored latex conjugate with a monoclonal antibody.

The claim coverage centers on distinct sample and solution migration paths that meet at a shared test site, with ligand-binding and selectively binding agents and delayed sample arrival, as well as marker-conjugate and HIV-1 p24 configurations.

Stated Advantages

The description reports at least an eight-fold sensitivity improvement for TB testing compared with prior-art devices.

The description reports approximately four-fold sensitivity improvement for HIV-1 and HIV-2 testing compared with prior-art devices.

The description identifies reduced false positives and faster migration as advantages.

Documented Applications

Testing for TB.

Testing for HIV-1 and HIV-2, including the described HIV-1 p24 embodiment.

Multiplex detection.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.